Upcoming catalysts
Trial resultsNVSNovartisH2 2026 Novartis expects to report results from its Phase 3 study of Pelacarsen (Lp(a)-lowering antisense; with Ionis) for Cardiovascular outcomes in patients with elevated Lp(a) and CVD in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- Phase 3 Lp(a) HORIZON topline for pelacarsen · Clinical trial results (readout / topline data)
- Drug
- Pelacarsen (Lp(a)-lowering antisense; with Ionis)
- For
- Cardiovascular outcomes in patients with elevated Lp(a) and CVD
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Reuters (July 20, 2026) lists pelacarsen among three major Novartis readouts due in H2 2026. Novartis had guided to mid-2026 (Ionis relayed Q2 2026 timing in February 2026) and data are now considered overdue/imminent. One of the most-watched cardiology catalysts of 2026.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Trial resultsNVSNovartisH2 2026 Novartis expects to report results from its Phase 3 study of Remibrutinib (oral BTK inhibitor, Rhapsido) for Relapsing multiple sclerosis in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- Phase 3 remibrutinib multiple sclerosis readout · Clinical trial results (readout / topline data)
- Drug
- Remibrutinib (oral BTK inhibitor, Rhapsido)
- For
- Relapsing multiple sclerosis
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Reuters (July 20, 2026) reports the remibrutinib MS Phase 3 readout is due in H2 2026 — one of three pivotal Novartis readouts analysts flag as critical to the stock's valuation premium.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Trial resultsNVSNovartisH2 2026 Novartis expects to report results from its Phase 3 study of Del-desiran (delpacibart etedesiran; Avidity Biosciences, being acquired by Novartis) for Myotonic dystrophy type 1 (DM1) in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- Pivotal del-desiran data in myotonic dystrophy type 1 (via Avidity) · Clinical trial results (readout / topline data)
- Drug
- Del-desiran (delpacibart etedesiran; Avidity Biosciences, being acquired by Novartis)
- For
- Myotonic dystrophy type 1 (DM1)
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Reuters (July 20, 2026) lists del-desiran pivotal data among the H2 2026 readouts that matter for Novartis, which agreed to acquire Avidity Biosciences. Multibillion-dollar peak sales potential per the report.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ApprovalNVSNovartisH2 2026 Novartis expects the FDA to decide on Cosentyx (secukinumab) for Polymyalgia rheumatica in the second half of 2026 (no exact date yet). An approval lets the company start selling it in that market.
More details
- Entry
- FDA approval expected for Cosentyx in polymyalgia rheumatica (PMR) · Regulatory approval
- Drug
- Cosentyx (secukinumab)
- For
- Polymyalgia rheumatica
- Stage
- sBLA under FDA review
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Novartis Q2 2026 investor presentation (Jul 21, 2026) lists Cosentyx PMR under H2 2026 regulatory decisions (US); CEO on the call said they are 'anticipating FDA approval for that indication in the second half'. US/EU/JP submissions were made in Q1 2026.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ApprovalNVSNovartisH2 2026 Novartis expects the FDA to decide on Rhapsido (remibrutinib) for Chronic inducible urticaria (symptomatic dermographism) in the second half of 2026 (no exact date yet). An approval lets the company start selling it in that market.
More details
- Entry
- FDA decision on Rhapsido (remibrutinib) in CIndU symptomatic dermographism · Regulatory approval
- Drug
- Rhapsido (remibrutinib)
- For
- Chronic inducible urticaria (symptomatic dermographism)
- Stage
- sNDA under FDA review
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 slides list Rhapsido CIndU US decision in H2 2026 (US filing for SD cohort made in 2025). Global filings across all three CIndU subtypes (EU, JP, CN) also planned 'later this year'.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
MilestoneNVSNovartisH2 2026 Rhapsido (remibrutinib) global filings across three CIndU subtypes (EU, JP, CN), expected in the second half of 2026 (no exact date yet). A company milestone for Novartis (Rhapsido (remibrutinib) for Chronic inducible urticaria (SD, cold, cholinergic)): a step in the program rather than a decision or a data readout.
More details
- Entry
- Rhapsido (remibrutinib) global filings across three CIndU subtypes (EU, JP, CN) · Company milestone
- Drug
- Rhapsido (remibrutinib)
- For
- Chronic inducible urticaria (SD, cold, cholinergic)
- Stage
- Phase III RemIND
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 call (Jul 21, 2026): RemIND met primary endpoint in cold and cholinergic urticaria in Q1; slides list Rhapsido CIndU EU/JP/CN submissions in H2 2026.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ApprovalNVSNovartisH2 2026 Novartis expects regulators to decide on Ianalumab (VAY736) for Sjögren's disease in the second half of 2026 (no exact date yet). An approval lets the company start selling it in that market.
More details
- Entry
- Ianalumab US approval/launch in Sjögren's disease expected H2 2026 · Regulatory approval
- Drug
- Ianalumab (VAY736)
- For
- Sjögren's disease
- Stage
- BLA under FDA review
- When
- H2 2026 · the company gave a window, not a day
- Source note
- US/EU/CN/JP submissions made in Q1 2026 (NEPTUNUS-1/2); Novartis guides to a US launch in H2 2026, implying FDA action in that window. CEO on Q2 call: 'on track for a U.S. launch in Sjögren's disease in the second half'.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Trial resultsNVSNovartisH2 2026 Novartis expects to report results from its Phase 2 study of Rhapsido (remibrutinib) for Hidradenitis suppurativa in the second half of 2026 (no exact date yet). Phase 2 is the stage that tests whether the drug actually works.
More details
- Entry
- Rhapsido (remibrutinib) Phase III RECHARGE 1/2 readout in hidradenitis suppurativa · Clinical trial results (readout / topline data)
- Drug
- Rhapsido (remibrutinib)
- For
- Hidradenitis suppurativa
- Stage
- Phase 2 · the stage that tests whether the drug actually works
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 slides list 'Rhapsido HS PhIII (RECHARGE 1 & 2)' under H2 2026 readouts with footnote 'Readout accelerated from 2027' (16-week primary).
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Trial resultsNVSNovartisH2 2026 Novartis expects to report results from its Phase 1 study of Ianalumab (VAY736) for Immune thrombocytopenia (1L) in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.
More details
- Entry
- Ianalumab Phase III VAYHIT-1 readout in first-line ITP · Clinical trial results (readout / topline data)
- Drug
- Ianalumab (VAY736)
- For
- Immune thrombocytopenia (1L)
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 investor presentation; CEO said 'on track for the ITP first-line readout in the second half of 2026'. Note VAYHIA (wAIHA) missed its primary endpoint in Q1 2026.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Trial resultsNVSNovartisH2 2026 Novartis expects to report results from its Phase II study of QCZ484 for Hypertension in the second half of 2026 (no exact date yet). This is the first look at whether the drug did what the company hoped.
More details
- Entry
- QCZ484 Phase II hypertension interim readout (Ph3-enabling) · Clinical trial results (readout / topline data)
- Drug
- QCZ484
- For
- Hypertension
- Stage
- Phase II
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 slides list 'QCZ484 HTN PhII' under H2 2026 readouts, footnoted as a Ph3-enabling interim readout.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Trial resultsNVSNovartisH2 2026 Novartis expects to report results from its Phase II (ASTRALS) study of VHB937 for Amyotrophic lateral sclerosis in the second half of 2026 (no exact date yet). This is the first look at whether the drug did what the company hoped.
More details
- Entry
- VHB937 Phase II ASTRALS readout in ALS · Clinical trial results (readout / topline data)
- Drug
- VHB937
- For
- Amyotrophic lateral sclerosis
- Stage
- Phase II (ASTRALS)
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 slides list 'VHB937 ALS PhII (ASTRALS)' under H2 2026 readouts.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
MilestoneNVSNovartisH2 2026 Pelacarsen US regulatory submission in Lp(a) CV risk reduction, expected in the second half of 2026 (no exact date yet). A company milestone for Novartis (Pelacarsen for Cardiovascular risk reduction in elevated Lp(a)): a step in the program rather than a decision or a data readout.
More details
- Entry
- Pelacarsen US regulatory submission in Lp(a) CV risk reduction · Company milestone
- Drug
- Pelacarsen
- For
- Cardiovascular risk reduction in elevated Lp(a)
- Stage
- Phase III (HORIZON)
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 slide 'Key innovation milestones in 2026' lists pelacarsen US submission in H2 2026, following the event-driven HORIZON readout also guided for H2 2026.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
MilestoneNVSNovartisH2 2026 Pelabresib EU submission in myelofibrosis, expected in the second half of 2026 (no exact date yet). A company milestone for Novartis (Pelabresib for Myelofibrosis): a step in the program rather than a decision or a data readout.
More details
- Entry
- Pelabresib EU submission in myelofibrosis · Company milestone
- Drug
- Pelabresib
- For
- Myelofibrosis
- Stage
- Phase 2 · the stage that tests whether the drug actually works
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 milestones slide lists pelabresib MF EU submission in H2 2026; a new Phase III for US/JP/CN registration started in Q2 2026.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
MilestoneNVSNovartisH2 2026 Phase III starts: farabursen in ADPKD and remibrutinib in food allergy, expected in the second half of 2026 (no exact date yet). A company milestone for Novartis (Farabursen; remibrutinib for ADPKD; food allergy): a step in the program rather than a decision or a data readout.
More details
- Entry
- Phase III starts: farabursen in ADPKD and remibrutinib in food allergy · Company milestone
- Drug
- Farabursen; remibrutinib
- For
- ADPKD; food allergy
- Stage
- Phase III FPFV
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Listed under H2 2026 in the Q2 2026 'Key innovation milestones in 2026' slide.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ApprovalNVSNovartisH1 2027 Novartis expects the FDA to decide on Del-zota (delpacibart zotadirsen) for Duchenne muscular dystrophy (exon 44 skipping) in the first half of 2027 (no exact date yet). An approval lets the company start selling it in that market.
More details
- Entry
- Del-zota (DMD44) US launch expected H1 2027, subject to FDA approval · Regulatory approval
- Drug
- Del-zota (delpacibart zotadirsen)
- For
- Duchenne muscular dystrophy (exon 44 skipping)
- Stage
- BLA (accelerated approval) under FDA review
- When
- H1 2027 · the company gave a window, not a day
- Source note
- BLA submitted to FDA in Q2 2026 (EXPLORE44 data, dystrophin surrogate). CEO on Q2 call: 'expect the first launch here in the first half of 2027'.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Trial resultsNVSNovartisH1 2027 Novartis expects to report results from its Phase III (BEYOND) study of Zigakibart for IgA nephropathy in the first half of 2027 (no exact date yet). This is the first look at whether the drug did what the company hoped.
More details
- Entry
- Zigakibart Phase III BEYOND readout in IgA nephropathy · Clinical trial results (readout / topline data)
- Drug
- Zigakibart
- For
- IgA nephropathy
- Stage
- Phase III (BEYOND)
- When
- H1 2027 · the company gave a window, not a day
- Source note
- Novartis Q2 2026 results release (Jul 21, 2026).
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Trial resultsNVSNovartis2027 Novartis expects to report results from its Phase III study of Ianalumab (VAY736) for Systemic lupus erythematosus; lupus nephritis during 2027 (no exact date yet). This is the first look at whether the drug did what the company hoped.
More details
- Entry
- Ianalumab Phase III readouts in SLE and lupus nephritis · Clinical trial results (readout / topline data)
- Drug
- Ianalumab (VAY736)
- For
- Systemic lupus erythematosus; lupus nephritis
- Stage
- Phase III
- When
- 2027 · the company gave a window, not a day
- Source note
- Q2 2026 investor presentation ianalumab slide; SSc Phase II also guided for 2027.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Trial resultsNVSNovartis2027 Novartis expects to report results from its Phase III CVOTs study of Leqvio (inclisiran) for ASCVD MACE reduction during 2027 (no exact date yet). This is the first look at whether the drug did what the company hoped.
More details
- Entry
- Leqvio cardiovascular outcomes trials (VICTORION-2 PREVENT / -1 PREVENT) readouts · Clinical trial results (readout / topline data)
- Drug
- Leqvio (inclisiran)
- For
- ASCVD MACE reduction
- Stage
- Phase III CVOTs
- When
- 2027 · the company gave a window, not a day
- Source note
- Novartis Q2 2026 earnings call (Jul 21, 2026).
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Trial resultsNVSNovartis2027 Novartis expects to report results from its Phase III study of Kesimpta (ofatumumab) for Relapsing multiple sclerosis during 2027 (no exact date yet). This is the first look at whether the drug did what the company hoped.
More details
- Entry
- Kesimpta every-two-month maintenance dosing Phase III readout · Clinical trial results (readout / topline data)
- Drug
- Kesimpta (ofatumumab)
- For
- Relapsing multiple sclerosis
- Stage
- Phase III
- When
- 2027 · the company gave a window, not a day
- Source note
- Q2 2026 Kesimpta brand slide.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Past catalysts
ConferenceNVSNovartisAug 31, 2026 Novartis presented data on Leqvio (inclisiran) for Hypercholesterolemia (LDL-C lowering) at a medical meeting on Aug 31, 2026. The linked source has the details.
More details
- Entry
- Leqvio VICTORION-CHALLENGE vs bempedoic acid late-breaking oral at ESC 2026 · Data presented at a medical meeting
- Drug
- Leqvio (inclisiran)
- For
- Hypercholesterolemia (LDL-C lowering)
- Stage
- Phase IV
- When
- Aug 31, 2026
- Source note
- Aug 19, 2026 Novartis ESC 2026 preview (ESC Congress Aug 29-31, 2026): head-to-head inclisiran vs bempedoic acid LDL-C goal attainment presented as a late-breaker.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ConferenceNVSNovartisAug 29, 2026 Novartis presented data on Pacibekitug for Inflammation in chronic kidney disease / CV risk at a medical meeting on Aug 29, 2026. The linked source has the details.
More details
- Entry
- TRANQUILITY pacibekitug (anti-IL-6) CKD inflammation data in ESC 2026 Hot Line · Data presented at a medical meeting
- Drug
- Pacibekitug
- For
- Inflammation in chronic kidney disease / CV risk
- Stage
- Phase II
- When
- Aug 29, 2026
- Source note
- Novartis ESC 2026 release (Aug 19, 2026); also AZALEA-TIMI 71 abelacimab bleeding analyses (Aug 29 oral).
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ConferenceNVSNovartisAug 19, 2026 Novartis presented data on Leqvio (inclisiran), abelacimab, Entresto, pacibekitug for ASCVD/LDL-C, atrial fibrillation, heart failure, CKD at a medical meeting on Aug 19, 2026. The linked source has the details.
More details
- Entry
- Novartis sets out 10 cardiovascular abstracts for ESC Congress 2026 · Data presented at a medical meeting
- Drug
- Leqvio (inclisiran), abelacimab, Entresto, pacibekitug
- For
- ASCVD/LDL-C, atrial fibrillation, heart failure, CKD
- Stage
- Phase III / Phase IV
- When
- Aug 19, 2026
- Source note
- Novartis announced data across Leqvio, abelacimab, Entresto and pacibekitug for the 2026 European Society of Cardiology Congress, spanning LDL-C lowering, AF bleeding and CKD cardiovascular risk.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ApprovalNVSNovartisJul 31, 2026 The FDA approved Novartis’ Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic hormone-sensitive prostate cancer on Jul 31, 2026. The company can now sell it in that market.
More details
- Entry
- FDA approves Pluvicto plus ARPI for PSMA+ metastatic hormone-sensitive prostate cancer · Regulatory approval
- Drug
- Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
- For
- PSMA-positive metastatic hormone-sensitive prostate cancer
- Stage
- Phase III / approved
- When
- Jul 31, 2026
- Source note
- Novartis said the FDA approved Pluvicto in combination with an androgen receptor pathway inhibitor in mHSPC, roughly doubling the eligible US patient population for the radioligand therapy.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ApprovalNVSNovartisJul 17, 2026 The FDA approved Novartis’ Fabhalta (iptacopan) for Primary IgA nephropathy at risk of progression on Jul 17, 2026. The company can now sell it in that market.
More details
- Entry
- FDA grants Fabhalta traditional approval to slow kidney decline in IgAN · Regulatory approval
- Drug
- Fabhalta (iptacopan)
- For
- Primary IgA nephropathy at risk of progression
- Stage
- Phase III / approved
- When
- Jul 17, 2026
- Source note
- The FDA converted Fabhalta's 2024 accelerated approval in primary IgA nephropathy to traditional approval under priority review, based on two-year eGFR slope data from APPLAUSE-IgAN.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ConferenceNVSNovartisJun 1, 2026 Novartis presented data on Cosentyx (secukinumab), ianalumab, rap-cel for Polymyalgia rheumatica, Sjogren's disease, PsA, SLE at a medical meeting on Jun 1, 2026. The linked source has the details.
More details
- Entry
- Novartis details EULAR 2026 immunology data incl. Cosentyx Phase III in PMR · Data presented at a medical meeting
- Drug
- Cosentyx (secukinumab), ianalumab, rap-cel
- For
- Polymyalgia rheumatica, Sjogren's disease, PsA, SLE
- Stage
- Phase III
- When
- Jun 1, 2026
- Source note
- Novartis announced 31 abstracts for EULAR 2026 (London, June 3-6), headlined by Phase III REPLENISH data for Cosentyx in polymyalgia rheumatica and ianalumab Sjogren's extension data.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ConferenceNVSNovartisMay 26, 2026 Novartis presented data on Vanrafia (atrasentan), Fabhalta (iptacopan), zigakibart for IgA nephropathy, C3 glomerulopathy, ADPKD at a medical meeting on May 26, 2026. The linked source has the details.
More details
- Entry
- Novartis flags late-breaking Phase III kidney data for ERA 2026 congress · Data presented at a medical meeting
- Drug
- Vanrafia (atrasentan), Fabhalta (iptacopan), zigakibart
- For
- IgA nephropathy, C3 glomerulopathy, ADPKD
- Stage
- Phase III
- When
- May 26, 2026
- Source note
- Ahead of the ERA Congress in Glasgow (June 3-6), Novartis announced 15 kidney abstracts including Phase III Vanrafia (atrasentan) and Fabhalta (iptacopan) data in IgAN and C3G.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ApprovalNVSNovartisMar 13, 2026 The FDA approved Novartis’ Cosentyx (secukinumab) for Moderate to severe hidradenitis suppurativa, patients 12+ on Mar 13, 2026. The company can now sell it in that market.
More details
- Entry
- FDA approves Cosentyx for adolescents 12+ with hidradenitis suppurativa · Regulatory approval
- Drug
- Cosentyx (secukinumab)
- For
- Moderate to severe hidradenitis suppurativa, patients 12+
- Stage
- Approved / registrational · a study designed to support approval
- When
- Mar 13, 2026
- Source note
- Novartis said the FDA cleared Cosentyx for moderate-to-severe HS in patients aged 12 and older, making it the only IL-17A inhibitor approved in that pediatric population.
- Checked
- Checked by a person when it was added
- Verify it
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page